CN116889581A - 三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 - Google Patents
三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 Download PDFInfo
- Publication number
- CN116889581A CN116889581A CN202211048945.1A CN202211048945A CN116889581A CN 116889581 A CN116889581 A CN 116889581A CN 202211048945 A CN202211048945 A CN 202211048945A CN 116889581 A CN116889581 A CN 116889581A
- Authority
- CN
- China
- Prior art keywords
- weight percent
- pseudo
- powder
- ginseng
- active composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 113
- 244000131316 Panax pseudoginseng Species 0.000 title claims abstract description 58
- 235000003181 Panax pseudoginseng Nutrition 0.000 title claims abstract description 58
- 239000008280 blood Substances 0.000 title claims abstract description 47
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 235000012054 meals Nutrition 0.000 title claims abstract description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title description 24
- 239000008103 glucose Substances 0.000 title description 24
- 150000002632 lipids Chemical class 0.000 title description 14
- 241000186660 Lactobacillus Species 0.000 claims abstract description 21
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 21
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 238000000855 fermentation Methods 0.000 claims description 79
- 230000004151 fermentation Effects 0.000 claims description 79
- 239000001963 growth medium Substances 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 21
- 240000008892 Helianthus tuberosus Species 0.000 claims description 19
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 19
- 235000013312 flour Nutrition 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 16
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 claims description 16
- 235000013325 dietary fiber Nutrition 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- CUFLZUDASVUNOE-UHFFFAOYSA-N Protocatechuic acid methyl ester Natural products COC(=O)C1=CC=C(O)C(O)=C1 CUFLZUDASVUNOE-UHFFFAOYSA-N 0.000 claims description 10
- 240000008042 Zea mays Species 0.000 claims description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 10
- 235000005822 corn Nutrition 0.000 claims description 10
- 229930182478 glucoside Natural products 0.000 claims description 10
- 238000011218 seed culture Methods 0.000 claims description 10
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 9
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 9
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 9
- 241000180649 Panax notoginseng Species 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 8
- 229940126902 Phlorizin Drugs 0.000 claims description 8
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 8
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 8
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 8
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 8
- LVFCLUMIBMHAFL-HMUNZLOLSA-N benzoyl-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC=CC=C1 LVFCLUMIBMHAFL-HMUNZLOLSA-N 0.000 claims description 8
- XOPOEBVTQYAOSV-UHFFFAOYSA-N butyl 3,4,5-trihydroxybenzoate Chemical compound CCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 XOPOEBVTQYAOSV-UHFFFAOYSA-N 0.000 claims description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000005487 catechin Nutrition 0.000 claims description 8
- 229950001002 cianidanol Drugs 0.000 claims description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 8
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims description 8
- 235000019139 phlorizin Nutrition 0.000 claims description 8
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 claims description 8
- 229960001285 quercetin Drugs 0.000 claims description 8
- 235000005875 quercetin Nutrition 0.000 claims description 8
- 235000021283 resveratrol Nutrition 0.000 claims description 8
- 229940016667 resveratrol Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 241001553290 Euphorbia antisyphilitica Species 0.000 claims description 6
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 4
- 244000000626 Daucus carota Species 0.000 claims description 4
- 235000002767 Daucus carota Nutrition 0.000 claims description 4
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 claims description 4
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 claims description 4
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 claims description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 4
- 229940114124 ferulic acid Drugs 0.000 claims description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 4
- 235000001785 ferulic acid Nutrition 0.000 claims description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- -1 methyl protocatechuic acid Chemical compound 0.000 claims description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- 229930013686 lignan Natural products 0.000 claims description 2
- 235000009408 lignans Nutrition 0.000 claims description 2
- 150000005692 lignans Chemical class 0.000 claims description 2
- BDCDNTVZSILEOY-UHFFFAOYSA-N polystachoside Natural products OC1C(O)C(CO)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-UHFFFAOYSA-N 0.000 claims description 2
- BDCDNTVZSILEOY-FWYGIPPASA-N quercetin-3-O-alpha-D-arabinofuranoside Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O BDCDNTVZSILEOY-FWYGIPPASA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 3
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims 1
- 240000006024 Lactobacillus plantarum Species 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 244000287839 Vaccinium bracteatum Species 0.000 claims 1
- 235000005480 Vaccinium bracteatum Nutrition 0.000 claims 1
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 1
- 229940099563 lactobionic acid Drugs 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 230000000968 intestinal effect Effects 0.000 abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 210000000056 organ Anatomy 0.000 abstract description 4
- 241000233866 Fungi Species 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 40
- 239000000284 extract Substances 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 35
- 235000010633 broth Nutrition 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 239000000835 fiber Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- 235000015278 beef Nutrition 0.000 description 10
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 229940099596 manganese sulfate Drugs 0.000 description 10
- 235000007079 manganese sulphate Nutrition 0.000 description 10
- 239000011702 manganese sulphate Substances 0.000 description 10
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 229940073490 sodium glutamate Drugs 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 6
- 239000001393 triammonium citrate Substances 0.000 description 6
- 235000011046 triammonium citrate Nutrition 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005462 in vivo assay Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 210000000593 adipose tissue white Anatomy 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000033116 oxidation-reduction process Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008505 β-D-glucopyranosides Chemical class 0.000 description 3
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000745390 Lophatherum Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical group C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical group N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013118 diabetic mouse model Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 101100102503 Caenorhabditis elegans ver-3 gene Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000318403 Houstonia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001046559 Marvinbryantia Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000204115 Sporolactobacillus inulinus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001857 fluorescence decay curve Methods 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108700004813 glycosylated insulin Proteins 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 239000006012 monoammonium phosphate Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
本申请公开了一种三七活性组合物、代餐粉以及其应用。该三七活性组合物包括15种活性成分以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉,对α‑葡萄糖苷酶抑制率不低于51.49%,OARC值不低于32.60μmolTE/mL。利用该三七活性组合物制作的代餐粉不仅对糖尿病模型鼠具有降糖降脂和减肥作用,对小鼠脏器损伤小,还对小鼠肠道菌群分析发现了本申请实施例提供的代餐粉具有提高小鼠肠道厚壁菌门丰度的作用,利于小鼠肠道微生态向益生方向转变。
Description
技术领域
本申请涉及三七技术领域,尤其涉及三七活性组合物、代餐粉及其在减肥降糖降脂中的应用。
背景技术
三七为寥科寥属植物中华抱茎寥(Polygouum amplexic-aide D.Donvar.siueu.se)的干燥根茎,是苗族和土家族的常用药材。中医理论认为其味涩、微苦,有活血舒筋、散癖止痛、抗菌消炎和止血生肌等功效,临床上用于跌打损伤、肠胃炎等疾病的治疗。现代药理学研究结果证明,三七具有抗真菌、抗氧化和辅助治疗动脉粥样硬化等作用。近年来文献报道,三七的活性成分在肿瘤防治方面也起到了重要的作用。但目前,针对三七生物活性成分及药理作用的研究仍较少,充分三七的活性成分,为进一步探究其更为广泛的应用价值具有十分现实重要的现实意义。
发明内容
有鉴于此,本申请的目的在于开发一种能够具有更为广阔应用前景的三七活性组合物以及其相关产品和应用。
第一方面,本申请实施例公开了一种三七活性组合物,包括白黎芦醇、根皮苷、槲皮素、6-甲氧基-7羟基香豆素、儿茶素、南烛木树脂酚、原儿茶酸甲酯、没食子酸甲酯、没食子酸正丁基酯、6-O-(E)-咖啡酰基葡萄糖苷、胡萝卜苷、苯甲酰基β-D-吡喃葡萄糖苷、2,8-三醇-1-O-β-D-吡喃葡糖苷、槲皮素-3-O-α-D-呋喃阿拉伯糖苷和阿魏酸以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
在本申请实施例中,所述三七活性组合物,按重量千分比计包含14.20~16.24wt‰白黎芦醇、16.48~18.16wt‰根皮苷、12.50~13.12wt‰槲皮素、4.69~4.95wt‰6-甲氧基-7羟基香豆素、6.498~6.622wt‰儿茶素、2.088~2.172wt‰南烛木树脂酚、1.053~1.127wt‰原儿茶酸甲酯、0.794~0.846wt‰没食子酸甲酯、0.612~0.648wt‰没食子酸正丁基酯、0.415~0.445wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.732~1.848wt‰胡萝卜苷、12.19~14.31wt‰苯甲酰基β-D-吡喃葡萄糖苷、3.68~4.56wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、5.153~5.327wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和9.23~10.87wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
在本申请实施例中,所述三七活性组合物,按重量千分比计包含11.93~14.61wt‰白黎芦醇、17.41~20.69wt‰根皮苷、9.18~11.08wt‰槲皮素、1.87~2.75wt‰6-甲氧基-7羟基香豆素、4.108~5.212wt‰儿茶素、1.732~1.788wt‰南烛木树脂酚、0.745~0.775wt‰原儿茶酸甲酯、0.317~0.363wt‰没食子酸甲酯、0.449~0.491wt‰没食子酸正丁基酯、0.546~0.574wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.426~1.534wt‰胡萝卜苷、16.93~19.39wt‰苯甲酰基β-D-吡喃葡萄糖苷、2.89~3.61wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、2.732~2.848wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和13.56~17.14wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
在本申请实施例中,所述三七活性组合物,按重量千分比计包含14.02~16.26wt‰白黎芦醇、12.21~14.69wt‰根皮苷、10.19~11.97wt‰槲皮素、4.42~4.94wt‰6-甲氧基-7羟基香豆素、7.744~7.896wt‰儿茶素、2.799~2.861wt‰南烛木树脂酚、1.189~1.311wt‰原儿茶酸甲酯、0.817~1.003wt‰没食子酸甲酯、0.738~0.782wt‰没食子酸正丁基酯、0.519~0.5761wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.448~1.612wt‰胡萝卜苷、9.52~11.94wt‰苯甲酰基β-D-吡喃葡萄糖苷、4.07~4.77wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、5.053~5.187wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和9.11~10.37wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
在本申请实施例中,所述三七活性组合物对α-葡萄糖苷酶抑制率不低于51.49%,OARC值不低于32.60μmol TE/mL。
第二方面,本申请实施例公开了一种减肥降糖降脂代餐粉,包括第一方面所述的三七活性组合物0.0001~10粉、可溶性膳食纤维50~80份以及其他食品学上可接受的辅料。
第三方面,本申请实施例公开了第一方面所述的三七活性组合物的制备方法,包括以下步骤:
制备含有菊糖芽孢乳杆菌活菌的工作种子液;
制备种子液,所述种子液由所述工作种子液接种至种子培养基中进行,于37℃培养18h得到所述种子液;
制备发酵液,所述发酵液由所述种子液接种至发酵培养基中培养,即可得到所述发酵液;以及
将所述发酵液经由浓缩和干燥,即可得到所述三七活性组合物;
其中,所述种子培养基包含2~5g/L菊芋全粉、6~20g/L三七粉、0.1~7g/L玉米粉和0.1~8g/L荞麦粉;所述发酵培养基包含3~6g/L菊芋全粉、8~20g/L三七粉、0.1~8g/L玉米粉和0.1~8g/L荞麦粉。
在本申请实施例中,制备所述工作种子液是由活化的菊糖芽孢乳杆菌接种至驯化培养基上进行驯化培养得到,所述驯化培养基包含8~18.0g/L菊芋全粉和2.0~12g/L三七粉。
在本申请实施例中,所述驯化培养包括依次在第一驯化培养基、第二驯化培养基和第三驯化培养基中进行的驯化培养,第一驯化培养基包含18.0g/L菊芋全粉和2.0g/L三七粉,第二驯化培养基包含10.0g/L菊芋全粉和10.0g/L三七粉,第三驯化培养基包含8.0g/L菊芋全粉和12.0g/L三七粉。
第四方面,本申请实施例公开了第一方面所述的三七活性组合物、或第二方面所述的制备方法制得的三七活性组合物在制备减肥降糖降脂相关保健品中的应用。
与现有技术相比,本申请至少具有以下有益效果:
本申请利用菊糖芽孢乳杆菌对三七粉进行发酵,制得了一种包含由菊糖芽孢乳杆菌活菌和三七相关降糖降脂活性成分的冻干粉,经过对该冻干粉中活性成分分析发现,采用本申请发酵方法,不仅能够充分提高和富集三七相关降糖降脂活性成分含量,还能全面富集这些有效成分,为其作为一种降糖降脂,有效减肥发挥作用的保健品提供了一种应用前景。
由此,本申请实施例进一步利用该冻干粉制作了一种代餐粉,并经过体内实验证实了该代餐粉对KK/Upj-Ay/J糖尿病模型鼠的降糖降脂以及减肥作用,对小鼠脏器损伤小,无明显毒副作用,还对小鼠肠道菌群分析发现了本申请实施例提供的代餐粉具有提高小鼠肠道厚壁菌门的丰度的作用,利用小鼠肠道微生态向益生方向转变。
附图说明
图1为本申请实施例1~3和对比例1~6发酵过程中的pH值变化。
图2为本申请体内试验提供的正常组小鼠脂肪细胞切片染色图。
图3为本申请体内试验提供的模型组小鼠脂肪细胞切片染色图。
图4为本申请体内试验提供的干预组(实施例1)小鼠脂肪细胞切片染色图。
图5为本申请体内试验提供的阳性对照组(实施例1)小鼠脂肪细胞切片染色图。
具体实施方式
为了使本申请的目的、技术方案及优点更加清楚明白,以下结合实施例对本申请进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本申请,并不用于限定本申请。
益生菌发酵
一、材料与方法
1、生物材料
三七,干货,研磨成粉,文山福万家。
辅料:荞麦粉购自兴化市裕丰食品有限公司,玉米粉购自西安四叶草生物科技有限公司。
菊糖芽孢乳杆菌(Sporolactobacillus inulinus,简称为SI),货号B81253,购自明舟生物。
2、制备工作种子液
将菊糖芽孢乳杆菌的冻干粉,使用葡萄糖酵母膏蛋白胨(GYP)培养基,进行活化,冻干粉的首次活化要全部用完,用0.5mL的上述培养液进行溶液,接种至GYP的固体平板上,33℃培养15~18h后,挑取单菌落,接种至驯化培养基上进行驯化培养。
具体的实施例1的实施过程中,驯化培养包括将活化的SI菌落接种至第一驯化培养基中进行驯化的步骤;第一驯化培养基的配方的一个具体实施例为:酪蛋白酶消化物10.0g,牛肉膏粉15.0g,柠檬酸三铵2.0g,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,菊芋全粉18.0g,三七粉2.0g,1.5gα-淀粉酶(夏盛FDY-2801)、1.2gβ-淀粉酶(夏盛FDG-2258)、吐温1mL,加蒸馏水至1000mL,煮沸溶解,调pH至7.0(20~25℃),121℃灭菌20min,冷却分装后,将经过活化的SI单菌落按照12wt%的接种量接站至驯化培养基中,于36℃培养15~18h后,即可得到工作种子液。
具体的实施例2的实施过程中,驯化培养的步骤包括将活性的SI菌落依次转接至第一、第二、第三驯化培养基中进行培养的步骤;第二驯化培养基包含10.0g/L菊芋全粉和10.0g/L三七粉,其余成分均与第一驯化培养基相同,接种量为10wt%,于38℃培养15~18h后;再次转接至第三驯化培养基中,第三驯化培养基包含8.0g/L菊芋全粉和12.0g/L三七粉,其余成分均与第一驯化培养基相同,接种量为10wt%,于38℃培养15~18h后,即可得到工作种子液。
具体的对比例1的实施过程中,其并未进行相关驯化培养的步骤,而是直接将活化的SI菌落接种中工作种子培养基中,对比例1使用的一个具体的工作种子培养基的配方包括20g/L葡萄糖,10g/L蛋白胨,10g/L牛肉膏,5g/L酵母膏,2g/L柠檬酸氢二铵,5g/L乙酸钠,2g/L磷酸氢二钾,0.25g/L硫酸锰,0.5g/L硫酸镁,1mL吐温80,pH6.4,121℃灭菌15min,于40℃培养16h,制成工作种子菌液OD600为值达到0.2以上。
3、制备种子液和发酵液
将上述实施例1、实施例2和对比例1分别制得的工作种子液,接种至种子培养基中,于37℃培养18h,一个具体的种子培养基配方包括:牛肉膏粉25.0g,菊芋全粉3.0g,三七粉12.0g,5.0g玉米粉,7.0g荞麦粉,2.0g柠檬酸三铵,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,吐温1mL,加蒸馏水至1000mL,煮沸溶解,调pH至7.0(20~25℃),121℃灭菌20min,冷却分装后,将工作种子液按照12wt%的接种量接站至种子培养基中,于36℃培养15~18h后,即可得到种子液。
将种子液按照8wt%的接种量接站至发酵培养基中培养,即可得到发酵液。一个具体的发酵培养基的配方包括:牛肉膏粉20.0g,菊芋全粉5.0g,三七粉15.0g,8.0g玉米粉,10.0g荞麦粉,2.0g柠檬酸三铵,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,吐温1mL,加蒸馏水至1000mL,煮沸溶解,121℃灭菌20min,冷却后装入发酵罐中。发酵前期不通无菌空气,40℃,随着细胞浓度(OD600值变大)增长,氧化还原电位和二氧化碳发生变化。培养4h后转入微氧培养阶段,根据氧化还原电位和二氧化碳变化控制无菌空气流量。发酵4~30h控制氧化还原电位在-150mV~-180mV,尾气二氧化碳含量在15%~20%,发酵30h后不再通无菌空气,56h后发酵结束。
一个实施例3的实施过程为:其使用的工作种子液与实施例1制得的工作种子液相同,但其实验的种子培养基和发酵培养基的配方均为:牛肉膏粉25.0g,菊芋全粉3.0g,三七粉12.0g,5.0g玉米粉,7.0g荞麦粉,2.0g柠檬酸三铵,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,吐温1mL,加蒸馏水至1000mL。
一个对比例2的实施过程为:其使用的工作种子液与实施例1制得的工作种子液相同,但其实验的种子培养基和发酵培养基的配方均为:20g/L葡萄糖,10g/L蛋白胨,10g/L牛肉膏,5g/L酵母膏,2g/L柠檬酸氢二铵,5g/L乙酸钠,2g/L磷酸氢二钾,0.25g/L硫酸锰,0.5g/L硫酸镁,1mL吐温80,pH7.0,121℃灭菌15min,于40℃培养56h;由此经发酵制得其发酵液。
一个对比例3的实施过程为:其使用的工作种子液与实施例2制得的工作种子液相同,但其使用的种子培养基和发酵培养基的配方均为:20g/L葡萄糖,10g/L蛋白胨,10g/L牛肉膏,5g/L酵母膏,2g/L柠檬酸氢二铵,5g/L乙酸钠,2g/L磷酸氢二钾,0.25g/L硫酸锰,0.5g/L硫酸镁,1mL吐温80,pH7.0,121℃灭菌15min,于40℃培养56h;由此经发酵制得其发酵液。
一个对比例4的实施过程为:其使用的工作种子液与对比例1制得的工作种子液相同,但其实验的种子培养基和发酵培养基的配方均为:20g/L葡萄糖,10g/L蛋白胨,10g/L牛肉膏,5g/L酵母膏,2g/L柠檬酸氢二铵,5g/L乙酸钠,2g/L磷酸氢二钾,0.25g/L硫酸锰,0.5g/L硫酸镁,1mL吐温80,pH7.0,121℃灭菌15min,于40℃培养56h;由此经发酵制得其发酵液。
一个对比例5的实施过程为:其使用的工作种子液与实施例1制得的工作种子液相同,但其实验的种子培养基和发酵培养基的配方均为:牛肉膏粉25.0g,菊芋全粉3.0g,葡萄糖粉20.0g,2.0g柠檬酸三铵,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,吐温1mL,加蒸馏水至1000mL,调节pH7.0,121℃灭菌15min,于40℃培养16h;由此经发酵制得其发酵液。
一个对比例6的实施过程为:其使用的工作种子液与实施例1制得的工作种子液相同,但其实验的种子培养基和发酵培养基的配方均为:牛肉膏粉25.0g,5.0g玉米粉,7.0g荞麦粉,2.0g柠檬酸三铵,乙酸钠5.0g,硫酸锰0.05g,硫酸镁0.2g,磷酸氢二钾2.0g,吐温1mL,加蒸馏水至1000mL,调节pH7.0,121℃灭菌15min,于40℃培养16h;由此经发酵制得其发酵液。
4、相关指标测定
收集实施例1~3和对比例1~6提供的发酵液进行如下相关指标的测定。
乳酸菌、酵母菌活菌数量的测定:采用稀释倒平板法,参考GB 4789-2010中酵母菌和乳酸菌菌落总数的测定方法。
pH测定:发酵液桑堪浆的pH直接用PB-10pH计测定量。
抗氧化能力的测定:以氧自由基吸收能力(Oxygen Radical AbsorbanceCapacityORAC)法测定上述各实施例和对比例制得的发酵液额的ORAC,结果以μmol TE/mL(μmol TE/g)表示。
测定方法为:在96孔板微孔中分别加入20μL稀释后的样品液及Trolox标准溶液(日本和纯药株式会社),再加入80μL 1.25μmol/L荧光素钠溶液(用pH为7.4的75mmol/L磷酸盐缓冲液配制)混合均匀,于37℃下避光反应10min;然后加入100μL 140mmol/L自由基产生剂AAPH(用pH为7.4的75mmol/L磷酸盐缓冲液配制),混匀后,将微孔板置于酶标仪中,在37℃下以激发波长485nm,发射波长520nm,进行多点循环测定,每2min测定一次各微孔荧光强度,测定时间一般设定在荧光衰减呈基线后为止。实验分为阴性对照组1、阴性对照组2和实验组。阴性对照组1的孔板小孔中未添加自由基产生剂AAPH。阴性对照组2的孔板小孔中未添加Trolox标准溶液。样品的抗氧化能力与自由基作用下荧光衰退曲线的延缓部分面积(Net AUC)直接相关。实验所得各微孔反应的荧光强度数据通过软件的输出后,经过SPSS进行统计处理。各孔的不同时间点的绝对荧光强度数据与阴性对照组1的荧光强度相比,折算成相对荧光强度f,以相对荧光强度采用近似积分法计算应该熄灭曲线下面积(AUC),则OARC值=[(AUC样品-AUC阴性对照组2)/(AUC标准品-AUC阴性对照组2)]×(Trolox标准溶液量/样品量)。
α-葡萄糖苷酶抑制率的测定:取50μL样品(各实施例和对比例提供的发酵液)于96孔无菌细胞板中,并加入含100μL 1u/mLα-葡萄糖苷酶(G5003-100UN)pH6.9的0.1M磷酸缓冲液,25℃反应10min后,继续添加50μL含1.5mM硝基苯-α-D-吡喃葡萄糖苷的pH6.9的0.1M磷酸缓冲液,混合均匀后,立即用酶标仪测定405nm下的吸光度值,以50μL pH6.9的0.1M磷酸缓冲液的孔板作为空白对照,根据公式计算α-葡萄糖苷酶抑制率(%)=(1-A样品/A空白)×100%。
单糖含量测定:将待测样品(各实施例和对比例提供的发酵液)加入2倍体积的无水乙醇超声处理30min后,8000rpm离心10min,0.22μm滤膜过滤后用于HPLC分析其中的单糖含量。色谱条件为:糖类分析用高效液相色谱柱(4.6mm×250mm,5μm,Cosmosil Sugar-D),柱温30℃,蒸发光检测器进行检测,ELSD漂移管温度为40℃;流动相为75%乙睛,流速为1mL/min,进样量为10μL;采用外标法定量分析单糖的含量。
有机酸含量测定:用一定量偏磷酸溶液提取样品,超声处理30min,8000rpm离心10min,取上清液,0.22μm滤膜过滤,用于HPLC分析。色谱条件为:Aquasil C18色谱柱(4.6mm×250mm,5μm);流动相为pH2.7的0.1%磷酸二氢铵,等度洗脱15min,流速1mL/min,进样量为20μL,检测波长210nm。采用外标法测定有机酸含量。
5、数据处理
所有测试数据均以平均值和标准偏差表示,应用SPSS13.0软件处理数据,并对每列数据进行多重比较和显著性差异标记。
二、结果
表1
由表1可知,实施例1~3提供的发酵液菊糖芽孢乳杆菌活菌数均显著高于对比例1~6(对比例4除外),由此说明采用本申请实施例提供的发酵方法能够提供更高活菌数的发酵液,表1中,“-”表示未检出。而由图1可知,从第0~56h的发酵过程看,各实施例1~3在发酵过程中,第0~12h过程中,发酵pH值迅速降低,发酵值36h后,发酵液pH值较为稳定;而除对比例4外,其他各对比例的发酵液pH值在发酵过程中均逐步降低,且发酵完成后的发酵液pH值均低于实施例。另外,由表1可知,实施例1~3最终发酵得到的发酵液中的有机酸含量较低;而对比例1~3最终得到的发酵液中有机酸含量较高,对比例4提供的发酵液中并未检出乙酸和柠檬酸,对比例5、6中的有机酸含量与实施例相当。
表2
表2列出了各发酵液中果糖和葡萄糖含量,以及各发酵液的OARC值和α-葡萄糖苷酶抑制率,表2中,“-”表示未检出。结果可知,实施例1~3提供的发酵液中果糖和葡萄糖含量显著低于对比例1~6,并且实施例3甚至并未检出单糖成分,由此说明本申请实施例提供的发酵液为低糖含量发酵液。
进一步的,由表2可知,实施例1~3提供的发酵液的OARC值和α-葡萄糖苷酶抑制率均显著高于对比例,由此说明,本申请实施例提供的菊糖芽孢乳杆菌发酵液具有优异的抗氧化和α-葡萄糖苷酶抑制功能。
发酵液活性成分分析
1、发酵液后处理
(1)浸膏
收集上述实施例1~3和对比例1~6分别制得的发酵液,于65℃条件下减压浓缩后,向浓缩液中加入至9倍体积的95%的乙醇水溶液中,磁力搅拌处理30min,2000rpm离心10min,取上清液减压浓缩,得到第一浸膏。
(2)提取
将浸膏用90%的甲醇溶解后用等体积的石油醚萃取3~5次,取其下层相,减压回收得到第二浸膏;
将第二浸膏依次用异丁醇、丙醇、四氢呋喃和丙酮萃取,每一级萃取后的下层浸膏或者溶液作为下一级的待萃取物。
由此,依次得到异丁醇萃取物、丙醇萃取物、四氢呋喃萃取物和丙酮萃取物,将这些萃取物分别减压浓缩和冷冻干燥,去除其中的溶剂,得到对应的冻干粉。
2、冻干粉的活性成分检测
对于异丁醇萃取物和丙醇萃取物采用反向液相色谱法进行检测,以WatersSunfire ODS C18柱(250mm×4.6mm,5μm)为色谱柱,流动相为乙腈-水,梯度洗脱,流速为1.0ml/min,检测波长为可变波长(0min,230nm;10min,283nm;25min,203nm),柱温为30℃,进样量为10μL。
供试品:将上述的异丁醇萃取物、丙醇萃取物、四氢呋喃萃取物和丙酮萃取物的冻干粉分别用对应的异丙醇、丙醇、四氢呋喃和丙酮作为溶剂,配制成1.0mg/mL的溶液,以作为供试品。
标准品:为本实验所涉及的标准品参照表3所示。
表3标准品
3、结果
表4
表4中列出了将实施例1~3和对比例1~6经过上述发酵方法得到的发酵液进行后处理,分别得到各自的异丁醇萃取物、丙醇萃取物、四氢呋喃萃取物和丙酮萃取物的冻干粉,再将这些冻干粉混合后,采用上述反相色谱法检测H1~H15占发酵液冻干粉重量百分比,“wt‰”表示重量千分比。另外,本申请还将三七的粉末直接作为对比例7,采用上述的浸膏和提取的步骤,得到异丁醇萃取物、丙醇萃取物、四氢呋喃萃取物和丙酮萃取物的冻干粉,再将这些冻干粉混合后,采用上述反相色谱法检测H1~H15化合物占三七的粉末的重量百分比。表4中,H1~H15化合物中未写明的成分代表未检出该化合物。
由表4可知,实施例1~3相对于对比例7,不仅Hi~H15的组分保留齐全,而且其含量比例提升了3个数据级,极大了富集了三七中的相关活性成分。
而对比例1和4,由于其发酵过程中使用了对比例1制得的工作种子液,使得其发酵液经过后期处理后,使得其萃取物冻干粉中的三七相关活性成分大量损失。而对比例2、3和6,由于其发酵过程中的培养基配方不同,同样导致其发酵液经过后期处理后,使得其萃取物冻干粉中的三七相关活性成分大量损失。对比例5制得的萃取物冻干粉中相关三七活性成分得以保留。
体内实验
一、材料与方法
1、实验动物
SPF级KK/Upj-Ay/J糖尿病模型小鼠,体重24.5±2.3g,雌雄各半,喂食60Co鼠料1025,广州市赛柏诺生物科技有限公司。
SPF级C56BL/6J小鼠,体重20.1±1.6g,雌雄各半,正常喂食,北京华阜康生物科技股份有限公司。
实验动物饲养在IVC笼具中,温度21~25℃,湿度40~70%。糖尿病模型小鼠饲喂专用高脂高能量饲料60Co鼠料1025,C57BL/6J小鼠饲喂SPF专用饲料,购自北京华阜康生物科技股份有限公司。
2、供试品
本实验将以上述实施例1~3和对比例1~7为基础制成一种代餐粉,以测试其对模型小鼠的降糖降脂以及减肥作用。具体可参照如下工艺制作:
将所有基础原料球磨到指定粒径,过100目筛后,采用倍散工艺技术,将可溶性膳食纤维组分、实施例1~3或对比例1~7提供的冻干粉以及其他辅料在三维混合机中进行预混合,即可得到所述代餐粉。
为此,本申请实施例还公开了一种具有降糖降脂以及减肥功能的代餐粉,其包括上述实施例1~3制得的冻干粉0.0001~10粉、可溶性膳食纤维50~80份以及其他食品学上可接受的辅料。
其中,实施例1~3制得的冻干粉为经过实施例1~3发酵制得的发酵液经过浓缩、冷冻干燥得到,冷冻干燥过程中可加入重量百分比不大于6wt%的冻干保护剂。具体的,冻干保护剂选自脱脂乳、蔗糖、海藻糖、葡聚糖和维生素C钠盐中的至少一种。
上述代餐粉的组份中,可溶性膳食纤维选自水溶性大豆膳食纤维、水溶性糙米纤维、水溶性胚芽精米纤维、水溶性性玉米纤维、水溶性大麦纤维、水溶性米糠纤维、水溶性根菜纤维、水溶性海带纤维、水溶性胡萝卜纤维、水溶性四季度纤维、水溶性红豆纤维、水溶性豌豆纤维、水溶性红薯纤维和水溶性裙带菜纤维中的至少一种。
上述代餐粉的组分中,食品学上可接受的辅料包括调味剂、风味剂和/或食品防腐剂。
具体的,本实验所涉及的供试品的代餐粉的配方参照表5所示。
表5
实施方式 | 配方 |
实施例1 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
实施例2 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
实施例3 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例1 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例2 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例3 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例4 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例5 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例6 | 发酵冻干粉8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
对比例7 | 三七的粉末8份、可溶性膳食纤维65份、L-谷氨酸钠0.5份 |
3、实验分组
适应性饲养1周后,开始实验,C57BL/6J小鼠设为正常对照组。将血糖值达到糖尿病诊断标准(即≧11.1mmol/L)的KK/Upj-Ay/J糖尿病模型小鼠按随机血糖水平随机分为模型组、干预组和阳性组,每组20只动物,雌雄各半。
干预组每日灌胃给药上述供试品两次,给药容积20mg/kg.bw,灌胃体积0.1mL/10g,间隔4h以上,连续给药4周。
阳性组小鼠每日灌胃盐酸二甲双肌胍的剂量为:第一周128mg/kg.bw,第二周204mg/kg.bw,第三周280mg/kg.bw,第四周到实验结束303mg/kg.bw,灌胃体积0.1mL/10g。
正常对照组和模型组给子等容积0.5%梭甲基纤维素钠。鼠房温度维持在20~24℃,白天和黑夜各12h,相对湿度60-65%左右。实验共进行4周。
4、体重和血糖监测
每周称重1次。血糖给药期间每周测随机血糖和空腹血糖1次,测空腹血糖前禁食不禁水4h。将小鼠尾尖用酒精棉球擦净,取血约2μL滴于血糖试纸上检测血糖值。
5、血脂四项、胰岛素、糖化血红蛋白检测以及组织病理检测
给药4周后,小鼠禁食不禁水16h后摘眼球采血,待其自然凝固后3000rpm离心10min分离血清。用生化分析仪(AU5800系列,BECKMAN)检测总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋自胆固醇(HDL-C)、低密度脂蛋自胆固醇(LDL-C)四项指标,采用INS ELISA试剂盒(货号:JL18382,江莱生物)检测胰岛素含量,糖化血红蛋白ELISA试剂盒(上海一研生物科技有限公司)检测糖化血红蛋白含量。并计算胰岛素敏感指数(insulinsensitivityindex,ISI),ISI为空腹血糖值与空腹血胰岛素值乘积的倒数,呈非正态分布,分析时取其自然对数值。
取各组中小鼠的适当大小的睾丸附件的附睾脂肪放入脂肪固定液瓶中固定,肝脏组织取肝脏最大叶中部大小为1cm的正方形块入中性甲醛固定液瓶中固定,固定时间24h,制作石蜡切片,并进行苏木精染色后,光学纤维镜观察。
数据分析:所有测试数据均以平均值和标准偏差表示,应用SPSS13.0软件处理数据,并对每列数据进行多重比较和显著性差异标记。
6、对小鼠肠道菌群的影响
(1)收集各组小鼠的粪便,采用CTAB方法从样本中提取基因组DNA;然后进行DNA扩增,扩增引物为F:cctaygggrbgcascag;R:ggactacnngggtatctaat,扩增产物进行琼脂糖凝胶电泳检测后,回收目的条带,使用genejettmgel提取试剂盒(Thermo S cientific)对混合PCR产物进行纯化。使用Thermofisher公司的Ion Plus Fragment Library Kit 48rxns构建文库,经过Qubit定量和文库检测是否合格,上机测序使用Thermofisher公司的IonSSTMXL。
(2)数据分析
首先应用Cutadapt(V1.9.1,http://cutadapt.readthedocs.io/en/stab/)对reads低质量部分剪切,根据Barcode得到reads中拆分出各样品的数据,截取初步质控得到的原始数据(Raw reads,Reads经过以上处理后还需要进行去除嵌合体序列的步骤,该序列通过(https://github.com/torognes/vsearch/)与物种注释数据库进行比对,去除其中的嵌合体序列,最后得到最终有效的数据(Clean Reads)。
使用Uparse软件(Uparse v7.0.1001,http://www.drive5.com/uparse/)对所有样品的Clean Reads进行聚类,97%的一致性(Identity)为默认值,将序列聚类成为OTUs(Operational Taxonomic Units,与此同时选取OTUs的代表性序列,依照算法原则,OTUs的代表序列是筛选出现频数最高的序列。用Mothur方法与SILVA132(http://www.arb-silva.de/)的S SSUrRNA数据库的方法对OTUs序列进行物种注释分析(设定阂值为0.8~1),最终获得分类学信息后统计各样本的群落组成分别:kingdom(界),phylum(门),class(纲),order(目),family(科),genus(属),species(种)。进行快速多序列比对,使用的是MUSCLE(Version3.8.31,http://www.drives.com/muscle/)软件。最后以样品中数据量最少的为标准将各组样品的数据均一化处理。
Qiime软件(Version 1.9.1)计算Observed-species,Chaol,R软件(Version2.15.3分析,多样性分析评价样本间物种差异的复杂度。
二、结果
表6
由表6可知,模型组小鼠的在实验第4周后的体重和随机血糖均显著升高,而阳性对照组小鼠的随机血糖虽然显著低于模型组,但是其对体重并未明显降低,说明其对模型小鼠不具有减肥作用。而干预组中,实施例1~3提供的代餐粉干预KK/Upj-Ay/J糖尿病模型小鼠第4周后,其体重和随机血糖均显著低于模型组和阳性对照组小鼠,并与正常组小鼠相差不大,由此说明本申请实施例以经过益生菌发酵的三七的发酵冻干粉为基础制得的代餐粉,对于KK/Upj-Ay/J糖尿病模型小鼠具有降糖和减肥功效。
表7
由表7可知,模型组小鼠的在实验第4周后的四项血脂均显著升高,而阳性对照组小鼠的随机血糖虽然显著低于模型组,但是仍然显著高于正常组,说明阳性药物对模型小鼠的降脂作用有限。而干预组中,实施例1~3提供的代餐粉干预KK/Upj-Ay/J糖尿病模型小鼠第4周后,其四项血脂均显著低于模型组和阳性对照组小鼠,并与正常组小鼠相差不大,由此说明本申请实施例以经过益生菌发酵的三七的发酵冻干粉为基础制得的代餐粉,对于KK/Upj-Ay/J糖尿病模型小鼠具有降脂功效。
进一步地,通过检测小鼠脏器指数和脂肪指数来整体反应药物干预对小鼠的健康状况和体脂含量的影响,结果如表8所示。
表8
由表8可知,模型组小鼠的BMI指数、Lee′s指数、白色脂肪指数和肝脏指数均显著高于正常组,说明模型组小鼠不仅存在高血糖血脂以及肥胖症状,还存在肝脏损伤的可能。而干预组中,实施例1~3提供的代餐粉对小鼠进行干预后,其BMI指数、Lee′s指数、白色脂肪的指数和肝脏指数均由显著降低,尤其是白色脂肪指数,由此说明本申请实施例提供的代餐粉不仅均有降糖降脂,减肥作用,对小鼠的脏器损伤也较小。
另外,如图2所示,正常小鼠的脂肪排列有序且形状规整,而模型组的脂肪细胞排列杂乱,大小不一,脂肪细胞膨胀,由于脂肪的异常堆积导致,脂肪细胞的大小可以反映机体的肥胖程度。图3中脂肪细胞的平均尺寸,模型组的脂肪平均尺寸极显著高于正常组;图4、5中,干预组(实施例1)和阳性对照均显著的降低小鼠脂肪细胞的尺寸,说明实施例提供的代餐粉具有良好减肥作用。
由于本申请实施例提供的代餐粉以经过益生菌发酵的三七的发酵液冻干粉为基础制备,本实验进一步考察了其对于各组小鼠的组成肠道菌群的各菌属的丰富度影响情况,结果如表9、10所示。
表9 Relative Abundance
表10 Relative Abundance
由表9、10所示,肠道内菌群主要以拟杆菌门(Bac.)和厚壁菌门(Fir.)为主,其次占据比例较少的有放线菌门(Act.)、脱铁杆菌门(Def.)、统微菌门(Tle.)、变形菌门(Pro.)等。其中,厚壁菌门主要包括乳杆菌(Lac.)、双歧杆菌属(Bif.)、布劳特氏菌属(Bla.),Marvinbryantia(Mar.)以及代餐粉中增加的菊糖芽孢乳杆菌(S.inulinus)等均为益生菌。
并且,相对正常组,模型组小鼠肠道菌群中,厚壁菌门的丰度降低,尤其是其中的双歧杆菌属和布劳特氏菌属,并且其肠道菌群中未定义菌群(undentified Bacteria)以及变形菌门(常为致病菌)显著增多,说明模型组小鼠的肠道微生态发生了病变,不利于其生理健康。而经过本申请实施例1~3提供的代餐粉干预后,小鼠菌群厚壁菌门的丰度显著升高,并且经过补充菊糖芽孢乳杆菌,其肠道菌群出现了一定丰度,而对比例5虽然经过前述实验证实了具有一定的降糖降脂作用,但是其菊糖芽孢乳杆菌的肠道丰度远远不及实施例1~3,由此说明了,对比例5在利用菊糖芽孢乳杆菌发酵过程中使用的发酵培养基对制得的发酵冻干粉中活菌数以及最终作用于小鼠肠道丰度均存在显著影响。而其他对比例干预小鼠后,其厚壁菌门的丰度升高作用不明显,不利于小鼠肠道微生态向益生方向转变。
以上所述,仅为本申请较佳的具体实施方式,但本申请的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本申请揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本申请的保护范围之内。
Claims (10)
1.一种三七活性组合物,包含白黎芦醇、根皮苷、槲皮素、6-甲氧基-7羟基香豆素、儿茶素、南烛木树脂酚、原儿茶酸甲酯、没食子酸甲酯、没食子酸正丁基酯、6-O-(E)-咖啡酰基葡萄糖苷、胡萝卜苷、苯甲酰基β-D-吡喃葡萄糖苷、2,8-三醇-1-O-β-D-吡喃葡糖苷、槲皮素-3-O-α-D-呋喃阿拉伯糖苷和阿魏酸以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
2.根据权利要求1所述的三七活性组合物,其特征在于,按重量千分比计包含14.20~16.24wt‰白黎芦醇、
16.48~18.16wt‰根皮苷、12.50~13.12wt‰槲皮素、4.69~4.95wt‰6-甲氧基-7羟基香豆素、6.498~6.622wt‰儿茶素、2.088~2.172wt‰南烛木树脂酚、1.053~1.127wt‰原儿茶酸甲酯、0.794~0.846wt‰没食子酸甲酯、0.612~0.648wt‰没食子酸正丁基酯、0.415~0.445wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.732~1.848wt‰胡萝卜苷、12.19~14.31wt‰苯甲酰基β-D-吡喃葡萄糖苷、3.68~4.56wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、5.153~5.327wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和9.23~10.87wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
3.根据权利要求1所述的三七活性组合物,其特征在于,按重量千分比计包含11.93~14.61wt‰白黎芦醇、
17.41~20.69wt‰根皮苷、9.18~11.08wt‰槲皮素、1.87~2.75wt‰6-甲氧基-7羟基香豆素、4.108~5.212wt‰儿茶素、1.732~1.788wt‰南烛木树脂酚、0.745~0.775wt‰原儿茶酸甲酯、0.317~0.363wt‰没食子酸甲酯、0.449~0.491wt‰没食子酸正丁基酯、0.546~0.574wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.426~1.534wt‰胡萝卜苷、16.93~19.39wt‰苯甲酰基β-D-吡喃葡萄糖苷、2.89~3.61wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、2.732~2.848wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和13.56~17.14wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
4.根据权利要求1所述的三七活性组合物,其特征在于,按重量千分比计包含14.02~16.26wt‰白黎芦醇、12.21~14.69wt‰根皮苷、10.19~11.97wt‰槲皮素、4.42~4.94wt‰6-甲氧基-7羟基香豆素、7.744~7.896wt‰儿茶素、2.799~2.861wt‰南烛木树脂酚、1.189~1.311wt‰原儿茶酸甲酯、0.817~1.003wt‰没食子酸甲酯、0.738~0.782wt‰没食子酸正丁基酯、0.519~0.5761wt‰6-O-(E)-咖啡酰基葡萄糖苷、1.448~1.612wt‰胡萝卜苷、9.52~11.94wt‰苯甲酰基β-D-吡喃葡萄糖苷、4.07~4.77wt%2,8-三醇-1-O-β-D-吡喃葡糖苷、5.053~5.187wt‰槲皮素-3-O-α-D-呋喃阿拉伯糖苷和9.11~10.37wt‰阿魏酸,以及不低于1亿/g的菊糖芽孢乳杆菌活菌粉。
5.根据权利要求1所述的三七活性组合物,其特征在于,所述三七活性组合物对α-葡萄糖苷酶抑制率不低于51.49%,OARC值不低于32.60μmol TE/mL。
6.一种减肥降糖降脂代餐粉,其特征在于,包括如权利要求1~5任一项所述的三七活性组合物0.0001~10粉、可溶性膳食纤维50~80份以及其他食品学上可接受的辅料。
7.权利要求1~5任一项所述的三七活性组合物的制备方法,其特征在于,包括以下步骤:
制备含有菊糖芽孢乳杆菌活菌的工作种子液;
制备种子液,所述种子液由所述工作种子液接种至种子培养基中进行,于37℃培养18h得到所述种子液;
制备发酵液,所述发酵液由所述种子液接种至发酵培养基中培养,即可得到所述发酵液;以及
将所述发酵液经由浓缩和干燥,即可得到所述三七活性组合物;
其中,所述种子培养基包含2~5g/L菊芋全粉、6~20g/L三七粉、0.1~7g/L玉米粉和0.1~8g/L荞麦粉;所述发酵培养基包含3~6g/L菊芋全粉、8~20g/L三七粉、0.1~8g/L玉米粉和0.1~8g/L荞麦粉。
8.根据权利要求7所述的制备方法,其特征在于,制备所述工作种子液是由活化的菊糖芽孢乳杆菌接种至驯化培养基上进行驯化培养得到,所述驯化培养基包含8~18.0g/L菊芋全粉和2.0~12g/L三七粉。
9.根据权利要求8所述的制备方法,其特征在于,所述驯化培养包括依次在第一驯化培养基、第二驯化培养基和第三驯化培养基中进行的驯化培养,第一驯化培养基包含18.0g/L菊芋全粉和2.0g/L三七粉,第二驯化培养基包含10.0g/L菊芋全粉和10.0g/L三七粉,第三驯化培养基包含8.0g/L菊芋全粉和12.0g/L三七粉。
10.权利要求1~5任一项所述的三七活性组合物、或权利要求7~9任一项所述的制备方法制得的三七活性组合物在制备减肥降糖降脂相关保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211048945.1A CN116889581A (zh) | 2022-08-30 | 2022-08-30 | 三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211048945.1A CN116889581A (zh) | 2022-08-30 | 2022-08-30 | 三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116889581A true CN116889581A (zh) | 2023-10-17 |
Family
ID=88309811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211048945.1A Pending CN116889581A (zh) | 2022-08-30 | 2022-08-30 | 三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116889581A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107691502A (zh) * | 2017-10-31 | 2018-02-16 | 银学庆 | 一种防治甘蓝病毒病的组合物及其制备方法 |
CN108391762A (zh) * | 2018-05-25 | 2018-08-14 | 大连根特生物工程技术有限公司 | 一种含有中药添加物的新型鸭子饲料及其制备方法 |
CN112868963A (zh) * | 2021-02-02 | 2021-06-01 | 台健生物科技(福建)有限公司 | 一种人参酵素的制备方法与应用 |
-
2022
- 2022-08-30 CN CN202211048945.1A patent/CN116889581A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107691502A (zh) * | 2017-10-31 | 2018-02-16 | 银学庆 | 一种防治甘蓝病毒病的组合物及其制备方法 |
CN108391762A (zh) * | 2018-05-25 | 2018-08-14 | 大连根特生物工程技术有限公司 | 一种含有中药添加物的新型鸭子饲料及其制备方法 |
CN112868963A (zh) * | 2021-02-02 | 2021-06-01 | 台健生物科技(福建)有限公司 | 一种人参酵素的制备方法与应用 |
Non-Patent Citations (4)
Title |
---|
张敏;龚慧;周冬初;: "血三七活性成分和药理作用研究进展", 中国医院用药评价与分析, vol. 19, no. 12, pages 1528 - 1531 * |
王海楼;任恒春;邹忠梅;: "血三七抗氧化活性成分研究", 中国药学杂志, vol. 46, no. 11, pages 819 - 822 * |
肖日传等: "中药发酵研究现状及展望", 广东药科大学学报, vol. 36, no. 6, pages 897 - 902 * |
钱志良;劳含章;沈永喜;孙建荣;: "菊糖芽孢乳杆菌DS 2-18中试规模的D-乳酸发酵研究", 工业微生物, vol. 41, no. 05, pages 73 - 75 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104509864B (zh) | 一种具有改善胃肠功能的营养保健食品及其制备方法 | |
CN104544086B (zh) | 一种可改善肠道菌群的保健食品及其制备方法 | |
CN104543679A (zh) | 一种含益生菌的保健食品及其制备方法 | |
CN107549817B (zh) | 一种辣木天然有机钙及其制备方法 | |
CN104543680A (zh) | 一种抗疲劳、改善胃肠功能的保健食品及其制备方法 | |
CN106942724A (zh) | 具有调节肠道菌群结构作用的组合物及其制备方法与应用 | |
CN113322216B (zh) | 一种副干酪乳杆菌b111h及其在代谢综合征中的应用 | |
CN110973423A (zh) | 红曲诺丽果饮料及其制备方法 | |
CN115287240A (zh) | 一株具有高尿酸血症及痛风防治作用的植物乳杆菌及其应用 | |
KR100803998B1 (ko) | 진피발효추출물, 그 제조방법 및 건강기능식품 | |
CN112691125B (zh) | 一种用于美白或者抗衰老的药物组合物及其制备方法、护肤品 | |
JP4671450B1 (ja) | ダイエット食品 | |
KR101091833B1 (ko) | 유산균을 이용한 sac 고함량 마늘 발효물의 제조방법 | |
KR20160126591A (ko) | 인삼류 발효 추출물의 제조방법, 이의 방법으로 제조된 인삼류 발효 추출물 및 이를 포함하는 건강기능식품 | |
KR20120106218A (ko) | 팽화 발효 홍삼농축액의 제조방법 | |
CN105535035A (zh) | 一种桦褐孔菌发酵培养组合物及其制备方法 | |
CN114209621B (zh) | 一种保湿、抗氧化的红曲发酵物及其制备方法与应用 | |
CN116889581A (zh) | 三七活性组合物、代餐粉及其在减肥降糖降脂中的应用 | |
CN108379284A (zh) | 黑虎掌膳食纤维提取物在制备治疗和/或预防肠道菌群失调相关疾病制剂中的用途 | |
KR20190046255A (ko) | 장건강 및 장개선 효능을 가지는 수수 및 팥 발효물 및 이의 제조방법 | |
CN114317313A (zh) | 酸樱桃提取物在制备降低尿酸或抑制痛风发作产品中的应用 | |
KR101228554B1 (ko) | 진피발효생성방법 및 이에 의한 진피발효생성물 | |
CN109793217A (zh) | 一种红曲沙棘籽粕粉的制备方法 | |
CN116637141B (zh) | 一种基于微生物发酵得栀子降尿酸代谢产物发酵浸膏的方法 | |
CN114651983B (zh) | 一种源于虾酱的具有降尿酸及抗氧化能力的凝结芽孢杆菌、方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhou Sen Inventor after: Wang Jun Inventor after: Wang Xiaojuan Inventor before: Wang Xiaojuan |
|
CB03 | Change of inventor or designer information |